RE: NO TOXICITYNo toxicity at doses tested. Compound still needs tweaking for bioavailability, and if the compound coax out better response rates at different doses with no increases in toxicity great, but we have to check these matters.
The NCI tests are designed to see if different dosages result in higher than 26 of 57 cell lines demonstrating greater than 50% inhibition in cancer cell growth. Imagine if 57 of 57 cell lines demonstrated inhibition above 50% across 5 dosages (ie some dosages coax out 50%+ on some lines, different dosages on others) . Next step is then testing toxicity and bioavailability.
The company is very pleased to report that in this test, GAP-107B8demonstrated greater than 50-per-cent inhibition in cancer cell growthin 26 of 57 cell lines (46 per cent of all cell lines), from all ninecancer types in the panel, indicating the potential for potent effectof this novel drug compound across a broad range of human cancers.